Novo Nordisk A/S buy Boston
Summary
This prediction ended on 08.08.16 with a price of €45.50. The BUY prediction by Boston finished with a performance of 6.08%. Boston has 50% into this predictionNovo Nordisk is a Danish pharmaceutical company that specializes in diabetes care and research. It is considered to be one of the largest companies in the world that focus exclusively on diabetes management, with a product portfolio that ranges from insulin treatment to obesity management. The company is listed on the Copenhagen Stock Exchange and has gained global recognition for its commitment to sustainable business practices and its contribution to diabetes research and treatment. Novo Nordisk has a strong financial track record and has consistently delivered solid returns to investors over the years.
Performance without dividends (%)
Name | 1w | 1m | 1y | 3y |
---|---|---|---|---|
Novo Nordisk A/S | - | - | - | - |
iShares Core DAX® | 1.280% | 1.027% | 11.234% | 16.273% |
iShares Nasdaq 100 | -2.457% | -4.650% | 23.181% | 39.418% |
iShares Nikkei 225® | -2.006% | -2.091% | 6.745% | 6.545% |
iShares S&P 500 | -0.662% | -1.246% | 22.521% | 40.218% |
Comments by Boston for this prediction
In the thread Novo Nordisk A/S diskutieren
Boston stimmt der Buy-Einschätzung von Yesyoucan zu
Boston stimmt am 05.02.2016 der Buy-Einschätzung von Yesyoucan mit dem Kursziel 70€ zu.
Überschrift: Yesyoucan stimmt dem Sentiment von 'Buy' zu
Nach dem Einbruch, trotz guter Zahlen, in dieser Woche jetzt erst recht ein Kauf!